The bidding window for Cedaar Textile SME IPO was open from June 30, 2025, to July 2, 2025. The IPO received 4,12,83,000 bids against 43,50,000 total shares offered.
The basis of allotment will be finalised today, July 3, 2025. Here’s how you can check the IPO allotment status.
Cedaar Textile IPO is a book-building issue of ₹60.90 crores, consisting entirely of a fresh issue of 43.50 lakh equity shares. The price band is set at ₹130 to ₹140 per share. The tentative listing on NSE Emerge is scheduled for July 7, 2025.
Fast Track Finsec Pvt Ltd is the book-running lead manager, and Skyline Financial Services is the registrar for the issue.
The net proceeds from the fresh issue will be used to
(July 2, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
37.88 |
Non-Institutional Investors |
5.04 |
Retail Individual Investors(RIIs) |
9.73 |
Total |
12.26 |
Click here to explore other Upcoming IPOs
As of 3 July 2025, Cedaar Textile IPO’s GMP stood at ₹10. The estimated listing price is ₹150, i.e., a 7.14% gain per share over the upper price band.
Source: Business Standard Report dated 3 July, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Cedaar Textile offers an extensive range of high-quality yarn, including Raw White Yarns, Melange Yarns, Solid Top Dyed Yarns, and Grey Fancy Yarns. Their yarn portfolio spans diverse fibres such as Cotton, Polyester, Acrylic, Viscose, Tencel, Modal, and other speciality fibres.
Click here to check out newly Listed IPOs
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here